Haemopoietic cell kinetics in humans treated with rGM‐CSF

Brian I. Lord, Howard Gurney, James Chang, Nicholas Thatcher, Derek Crowther, T. Michael Dexter

Research output: Contribution to journalArticleResearchpeer-review

Abstract

We have investigated the kinetics of myeloid cell proliferation in the marrow of patients with small‐cell lung cancer and treated with 10 daily subcutaneous injections of granulocyte/macrophage colony‐stimulating factor (GM‐CSF). Bone marrow, obtained before and during treatment with the growth factor, was labelled in vitro with tritiated thymidine (3H‐TdR). A 3rd bone‐marrow sample was obtained I hr following an intravenous injection of 3H‐TdR. Subsequent daily blood samples were also collected, and 3H‐TdR labelling was assessed on these and the marrow preparations by autoradiography. GMCSF treatment increased the peripheral granulocytic cells nearly 5‐fold, but this included significant eosinophilia, so that the neutrophilic granulocytes increased only 3.3‐fold. These cells were released from the marrow over a normal time scale, but their peripheral half‐life was about 6 times longer than normal and they were probably functionally defective. Furthermore, significant numbers of immature cells were released from the marrow. Neutrophil production stimulated by GM‐CSF was thus overestimated by measurement of the apparent peripheral granulocytosis. Increased labelling indices and grain counts in the proliferating granulocytic cells of the marrow indicate shortened cell‐cycle times, and the excess granulocyte production appears to be the result of extra amplification divisions in the proliferative compartments.

LanguageEnglish
Pages26-31
Number of pages6
JournalInternational Journal of Cancer
Volume50
Issue number1
DOIs
Publication statusPublished - 1992
Externally publishedYes

Fingerprint

Bone Marrow
Granulocyte-Macrophage Colony-Stimulating Factor
Granulocytes
Small Cell Lung Carcinoma
Eosinophilia
Myeloid Cells
Subcutaneous Injections
Autoradiography
Intravenous Injections
Thymidine
Half-Life
Intercellular Signaling Peptides and Proteins
Cell Cycle
Neutrophils
Cell Count
Cell Proliferation
Therapeutics

Cite this

Lord, B. I., Gurney, H., Chang, J., Thatcher, N., Crowther, D., & Dexter, T. M. (1992). Haemopoietic cell kinetics in humans treated with rGM‐CSF. International Journal of Cancer, 50(1), 26-31. https://doi.org/10.1002/ijc.2910500107
Lord, Brian I. ; Gurney, Howard ; Chang, James ; Thatcher, Nicholas ; Crowther, Derek ; Dexter, T. Michael. / Haemopoietic cell kinetics in humans treated with rGM‐CSF. In: International Journal of Cancer. 1992 ; Vol. 50, No. 1. pp. 26-31.
@article{e7b42d253931410aa54eaabdddbd5586,
title = "Haemopoietic cell kinetics in humans treated with rGM‐CSF",
abstract = "We have investigated the kinetics of myeloid cell proliferation in the marrow of patients with small‐cell lung cancer and treated with 10 daily subcutaneous injections of granulocyte/macrophage colony‐stimulating factor (GM‐CSF). Bone marrow, obtained before and during treatment with the growth factor, was labelled in vitro with tritiated thymidine (3H‐TdR). A 3rd bone‐marrow sample was obtained I hr following an intravenous injection of 3H‐TdR. Subsequent daily blood samples were also collected, and 3H‐TdR labelling was assessed on these and the marrow preparations by autoradiography. GMCSF treatment increased the peripheral granulocytic cells nearly 5‐fold, but this included significant eosinophilia, so that the neutrophilic granulocytes increased only 3.3‐fold. These cells were released from the marrow over a normal time scale, but their peripheral half‐life was about 6 times longer than normal and they were probably functionally defective. Furthermore, significant numbers of immature cells were released from the marrow. Neutrophil production stimulated by GM‐CSF was thus overestimated by measurement of the apparent peripheral granulocytosis. Increased labelling indices and grain counts in the proliferating granulocytic cells of the marrow indicate shortened cell‐cycle times, and the excess granulocyte production appears to be the result of extra amplification divisions in the proliferative compartments.",
author = "Lord, {Brian I.} and Howard Gurney and James Chang and Nicholas Thatcher and Derek Crowther and Dexter, {T. Michael}",
year = "1992",
doi = "10.1002/ijc.2910500107",
language = "English",
volume = "50",
pages = "26--31",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "John Wiley & Sons",
number = "1",

}

Lord, BI, Gurney, H, Chang, J, Thatcher, N, Crowther, D & Dexter, TM 1992, 'Haemopoietic cell kinetics in humans treated with rGM‐CSF', International Journal of Cancer, vol. 50, no. 1, pp. 26-31. https://doi.org/10.1002/ijc.2910500107

Haemopoietic cell kinetics in humans treated with rGM‐CSF. / Lord, Brian I.; Gurney, Howard; Chang, James; Thatcher, Nicholas; Crowther, Derek; Dexter, T. Michael.

In: International Journal of Cancer, Vol. 50, No. 1, 1992, p. 26-31.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Haemopoietic cell kinetics in humans treated with rGM‐CSF

AU - Lord, Brian I.

AU - Gurney, Howard

AU - Chang, James

AU - Thatcher, Nicholas

AU - Crowther, Derek

AU - Dexter, T. Michael

PY - 1992

Y1 - 1992

N2 - We have investigated the kinetics of myeloid cell proliferation in the marrow of patients with small‐cell lung cancer and treated with 10 daily subcutaneous injections of granulocyte/macrophage colony‐stimulating factor (GM‐CSF). Bone marrow, obtained before and during treatment with the growth factor, was labelled in vitro with tritiated thymidine (3H‐TdR). A 3rd bone‐marrow sample was obtained I hr following an intravenous injection of 3H‐TdR. Subsequent daily blood samples were also collected, and 3H‐TdR labelling was assessed on these and the marrow preparations by autoradiography. GMCSF treatment increased the peripheral granulocytic cells nearly 5‐fold, but this included significant eosinophilia, so that the neutrophilic granulocytes increased only 3.3‐fold. These cells were released from the marrow over a normal time scale, but their peripheral half‐life was about 6 times longer than normal and they were probably functionally defective. Furthermore, significant numbers of immature cells were released from the marrow. Neutrophil production stimulated by GM‐CSF was thus overestimated by measurement of the apparent peripheral granulocytosis. Increased labelling indices and grain counts in the proliferating granulocytic cells of the marrow indicate shortened cell‐cycle times, and the excess granulocyte production appears to be the result of extra amplification divisions in the proliferative compartments.

AB - We have investigated the kinetics of myeloid cell proliferation in the marrow of patients with small‐cell lung cancer and treated with 10 daily subcutaneous injections of granulocyte/macrophage colony‐stimulating factor (GM‐CSF). Bone marrow, obtained before and during treatment with the growth factor, was labelled in vitro with tritiated thymidine (3H‐TdR). A 3rd bone‐marrow sample was obtained I hr following an intravenous injection of 3H‐TdR. Subsequent daily blood samples were also collected, and 3H‐TdR labelling was assessed on these and the marrow preparations by autoradiography. GMCSF treatment increased the peripheral granulocytic cells nearly 5‐fold, but this included significant eosinophilia, so that the neutrophilic granulocytes increased only 3.3‐fold. These cells were released from the marrow over a normal time scale, but their peripheral half‐life was about 6 times longer than normal and they were probably functionally defective. Furthermore, significant numbers of immature cells were released from the marrow. Neutrophil production stimulated by GM‐CSF was thus overestimated by measurement of the apparent peripheral granulocytosis. Increased labelling indices and grain counts in the proliferating granulocytic cells of the marrow indicate shortened cell‐cycle times, and the excess granulocyte production appears to be the result of extra amplification divisions in the proliferative compartments.

UR - http://www.scopus.com/inward/record.url?scp=0026600986&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910500107

DO - 10.1002/ijc.2910500107

M3 - Article

VL - 50

SP - 26

EP - 31

JO - International Journal of Cancer

T2 - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -